A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy

A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy

Sponsor: Karyopharm
Protocol Number: IST-321
Start Date: 31-AUG-2023
End Date: Active/Enrolling, projected trial end date 01/2024